全球腺相关病毒（AAV）合约开发和生产组织（CDMO）市场规模、份额、趋势和成长分析报告（2026-2034年）

预计到 2034 年，AAV 合约开发和生产组织 (CDMO) 市场规模将从 2025 年的 9.3 亿美元成长至 40 亿美元，2026 年至 2034 年的复合年增长率为 17.61%。

由于对使用腺结合病毒(AAV) 载体的基因疗法的需求不断增长，全球 AAV 合约开发和生产组织 (CDMO) 市场正经历快速成长。製药和生物技术公司越来越依赖专业的 CDMO 来开发和生产这些复杂的产品。针对罕见疾病和遗传疾病的基因治疗候选药物管线的扩展是推动 AAV 生产服务需求的主要因素。

主要成长要素包括企业内部生产的高成本和技术复杂性，促使企业将生产外包给经验丰富的合约研发生产机构 (CDMO)。病毒载体生产技术的进步和生产设施的扩建也促进了市场成长。基因疗法监管核准的增加导致对可靠生产合作伙伴的需求上升。创业投资公司的大力投资和策略合作进一步加速了市场发展。

展望未来，随着更多基因疗法进入商业化阶段，市场预计将显着成长。 CDMO公司正在扩大产能并投资先进技术，以满足日益增长的需求。可扩展生产流程的持续创新将提高效率并降低生产成本。随着基因治疗产业的成熟，AAV CDMO市场将在支持大规模生产和全球分销方面发挥关键作用。

目录

第一章：引言

第二章执行摘要

第三章 市场变数、趋势与框架

• 市场谱系展望
• 渗透率和成长前景分析
• 价值链分析
• 法律规范
  • 标准与合规性
  • 监管影响分析
• 市场动态
  • 市场驱动因素
  • 市场限制因素
  • 市场机会
  • 市场挑战
• 波特五力分析
• PESTLE分析

第四章：全球AAV合约开发与生产组织（CDMO）市场：依工作流程划分

• 市场分析、洞察与预测
• 上游工程
• 下游加工

第五章：全球腺相关病毒（AAV）合约开发与生产组织（CDMO）市场：依培养类型划分

• 市场分析、洞察与预测
• 黏附培养
• 悬浮培养

第六章：全球腺相关病毒（AAV）合约开发与生产组织（CDMO）市场：按应用领域划分

• 市场分析、洞察与预测
• 细胞和基因治疗开发
• 疫苗研发
• 生物製药和药物发现
• 生物医学研究

第七章：全球腺相关病毒（AAV）合约开发与生产组织（CDMO）市场：按最终用户划分

• 市场分析、洞察与预测
• 製药和生物製药公司
• 学术研究机构

第八章：全球腺相关病毒（AAV）合约开发与生产组织（CDMO）市场：按地区划分

• 区域分析
• 北美市场分析、洞察与预测
  • 我们
  • 加拿大
  • 墨西哥
• 欧洲市场分析、洞察与预测
  • 英国
  • 法国
  • 德国
  • 义大利
  • 俄罗斯
  • 其他欧洲国家
• 亚太市场分析、洞察与预测
  • 印度
  • 日本
  • 韩国
  • 澳洲
  • 东南亚
  • 其他亚太国家
• 拉丁美洲市场分析、洞察与预测
  • 巴西
  • 阿根廷
  • 秘鲁
  • 智利
  • 其他拉丁美洲国家
• 中东和非洲市场分析、洞察与预测
  • 沙乌地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中东和非洲国家

第九章 竞争情势

• 最新趋势
• 公司分类
• 供应链和销售管道合作伙伴（根据现有资讯）
• 市场占有率和市场定位分析（基于现有资讯）
• 供应商情况（基于现有资讯）
• 策略规划

第十章：公司简介

• 主要公司的市占率分析
• 公司简介
  • Thermo Fisher Scientific Inc
  • Creative Biogene
  • Catalent Inc
  • Charles River Laboratories International Inc
  • Danaher（Aldevron）
  • Forge Biologics
  • Genezen
  • ViroCell Biologics
  • Merck KGaA
  • Viralgen
  • Biovian Oy

The AAV Contract Development And Manufacturing Organizations Market size is expected to reach USD 4.00 Billion in 2034 from USD 0.93 Billion (2025) growing at a CAGR of 17.61% during 2026-2034.

The Global AAV Contract Development And Manufacturing Organizations (CDMO) Market is witnessing rapid growth due to the increasing demand for gene therapies that use adeno-associated virus (AAV) vectors. Pharmaceutical and biotechnology companies often rely on specialized CDMOs to develop and manufacture these complex products. The growing pipeline of gene therapy candidates targeting rare and inherited diseases is significantly driving the need for AAV production services.

Major growth drivers include the high cost and technical complexity of in-house manufacturing, which encourages companies to outsource to experienced CDMOs. Advancements in viral vector production technologies and the expansion of manufacturing facilities are also contributing to market growth. Increased regulatory approvals for gene therapies have created greater demand for reliable manufacturing partners. Strong investment from venture capital firms and strategic collaborations are further accelerating market development.

Looking forward, the market is expected to grow substantially as more gene therapies reach commercialization stages. CDMOs are expanding their production capacities and investing in advanced technologies to meet rising demand. Continuous innovation in scalable manufacturing processes will improve efficiency and reduce production costs. As the gene therapy industry matures, the AAV CDMO market will play a crucial role in supporting large-scale production and global distribution.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Workflow

• Upstream Processing
• Downstream Processing

By Culture Type

• Adherent Culture
• Suspension Culture

By Application

• Cell & Gene Therapy Development
• Vaccine Development
• Biopharmaceutical & Pharmaceutical Discovery
• Biomedical Research

By End-user

• Pharmaceutical & Biopharmaceutical Companies
• Academic & Research Institutes

COMPANIES PROFILED

• Thermo Fisher Scientific Inc, Creative Biogene, Catalent Inc, Charles River Laboratories International Inc, Danaher Aldevron, Forge Biologics, Genezen, ViroCell Biologics, Merck KGaA, Viralgen, Biovian Oy
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL AAV CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATIONS MARKET: BY WORKFLOW 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Workflow
• 4.2. Upstream Processing Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Downstream Processing Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL AAV CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATIONS MARKET: BY CULTURE TYPE 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Culture Type
• 5.2. Adherent Culture Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Suspension Culture Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL AAV CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATIONS MARKET: BY APPLICATION 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Application
• 6.2. Cell & Gene Therapy Development Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Vaccine Development Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Biopharmaceutical & Pharmaceutical Discovery Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.5. Biomedical Research Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL AAV CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATIONS MARKET: BY END-USER 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast End-user
• 7.2. Pharmaceutical & Biopharmaceutical Companies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Academic & Research Institutes Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL AAV CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATIONS MARKET: BY REGION 2022-2034(USD MN)

• 8.1. Regional Outlook
• 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.2.1 By Workflow
  • 8.2.2 By Culture Type
  • 8.2.3 By Application
  • 8.2.4 By End-user
  • 8.2.5 United States
  • 8.2.6 Canada
  • 8.2.7 Mexico
• 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.3.1 By Workflow
  • 8.3.2 By Culture Type
  • 8.3.3 By Application
  • 8.3.4 By End-user
  • 8.3.5 United Kingdom
  • 8.3.6 France
  • 8.3.7 Germany
  • 8.3.8 Italy
  • 8.3.9 Russia
  • 8.3.10 Rest Of Europe
• 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.4.1 By Workflow
  • 8.4.2 By Culture Type
  • 8.4.3 By Application
  • 8.4.4 By End-user
  • 8.4.5 India
  • 8.4.6 Japan
  • 8.4.7 South Korea
  • 8.4.8 Australia
  • 8.4.9 South East Asia
  • 8.4.10 Rest Of Asia Pacific
• 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.5.1 By Workflow
  • 8.5.2 By Culture Type
  • 8.5.3 By Application
  • 8.5.4 By End-user
  • 8.5.5 Brazil
  • 8.5.6 Argentina
  • 8.5.7 Peru
  • 8.5.8 Chile
  • 8.5.9 South East Asia
  • 8.5.10 Rest of Latin America
• 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.6.1 By Workflow
  • 8.6.2 By Culture Type
  • 8.6.3 By Application
  • 8.6.4 By End-user
  • 8.6.5 Saudi Arabia
  • 8.6.6 UAE
  • 8.6.7 Israel
  • 8.6.8 South Africa
  • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

• 9.1. Recent Developments
• 9.2. Company Categorization
• 9.3. Supply Chain & Channel Partners (based on availability)
• 9.4. Market Share & Positioning Analysis (based on availability)
• 9.5. Vendor Landscape (based on availability)
• 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL AAV CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATIONS INDUSTRY

• 10.1. Top Companies Market Share Analysis
• 10.2. Company Profiles
  • 10.2.1 Thermo Fisher Scientific Inc
  • 10.2.2 Creative Biogene
  • 10.2.3 Catalent Inc
  • 10.2.4 Charles River Laboratories International Inc
  • 10.2.5 Danaher (Aldevron)
  • 10.2.6 Forge Biologics
  • 10.2.7 Genezen
  • 10.2.8 ViroCell Biologics
  • 10.2.9 Merck KGaA
  • 10.2.10 Viralgen
  • 10.2.11 Biovian Oy